Smarter leaders trust GlobalData

Data Insights Innovation in Pharmaceuticals: Tyrosine kinase inhibitors

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

Pfizer Inc

View all

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

80+ innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 730,000 patents, there are 80+ innovation areas that will shape the future of the industry.

Within the emerging innovation stage, engineered multispecific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Peptide pharmacophores, antibody-drug conjugates and neuroprotective drugs are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are amyloid precursor targeted therapies and modified vector HIV-1 vaccines, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Tyrosine kinase inhibitors is a key innovation area in pharmaceutical industry

Tyrosine kinases catalyze the phosphorylation of select tyrosine residues in target proteins by using adenosine triphosphate (ATP). They can be divided into receptor tyrosine kinases (RTKs), non-receptor tyrosine kinases (NRTKs), and a few dual-specificity kinases (DSKs), which can phosphorylate serine, threonine, and tyrosine residues. Tyrosine kinase inhibitors (TKIs) are a group of drugs that interfere with the signal transduction pathways of protein kinases, compete with ATP for the ATP binding site of PTK, and reduce tyrosine kinase phosphorylation, thereby inhibiting the proliferation of cancer cells.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 105+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of tyrosine kinase inhibitors.

Key players in tyrosine kinase inhibitors – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to tyrosine kinase inhibitors

Seattle Children's Hospital is the leading patent filer in tyrosine kinase inhibitors. Seattle Children's Hospital is a healthcare center that offers pediatric and adolescent services. The center conducts pediatric research and provides patient care services. It has operations in Seattle, Everett, Bothell, Wenatchee, Richland and Federal Way.

F. Hoffmann-La Roche, Cell Signaling Technology, and Pfizer are the other key patent filers in the tyrosine kinase inhibitors space.

In terms of application diversity, OncoPlex Diagnostics is the top company, followed by The Children’s Hospital and Cell Signaling Technology.

By means of geographic reach, Arog Pharmaceuticals holds the top position, while NMS Group and OncoPlex Diagnostics stand in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.